We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer/Oncology
-
2. Cancer vaccines
- Dr. Elias Sayour
-
3. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
5. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
6. How liver X receptor regulates intestinal regeneration and tumor growth
- Dr. Srustidhar Das
- Neurology/Neuroscience
-
7. Integrated multimodal cell atlas of Alzheimer’s disease
- Dr. Michael Hawrylycz
-
8. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
9. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
10. Advancing ALS genetics through accessible testing
- Dr. Teresa Fecteau
-
11. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
12. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
13. Muscarinic acetylcholine receptor modulation in neurological diseases- Prof. Andrew B. Tobin
- Immunology & Inflammation
-
14. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
15. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
16. Decoy-resistant IL18: how engineered E. coli enhances immune responses against tumors- Dr. Rizwan Romee
-
17. Transmembrane domains and the regulation of trogocytosis in T cells
- Dr. Stefano Barbera
- Infectious Diseases/Microbiology
-
20. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
22. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Pharmaceutical Sciences
-
23. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
24. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
26. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
27. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
28. The regulation of cell therapy
- Prof. Moutih Rafei
-
29. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
30. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
32. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
33. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
- Methods
-
34. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
35. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
36. MassBank development and future
- Dr. Emma L. Schymanski
-
37. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
38. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
Topics Covered
- The challenge of developing influenza vaccines
- What is a universal influenza vaccine and how feasible is it?
- Current achievements and problems in the development of a universal influenza vaccine
- The problem of predicting efficacy of universal vaccines and the limits of model animals
Biography
Peter Palese is Chair and Professor of Microbiology, and Professor of Medicine at the Mount Sinai School of Medicine in New York. His research has focused on studying negative-strand RNA viruses with emphasis on influenza viruses. His laboratory developed the first reverse genetics system for negative-strand RNA viruses. He is a member of the National Academy of Sciences.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Palese, P. (2018, April 1). Towards developing a universal influenza vaccine [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 4, 2026, from https://doi.org/10.69645/PMWV3993.Export Citation (RIS)
Publication History
- Published on April 1, 2018
Financial Disclosures
- Prof. Peter Palese, Royalty, Receipt of Intellectual Property Rights/Patent Holder: Merck, S & D, GSK, Medi-immune, Avimed
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Professor Palese, thank you for sparing the time today.
I very much enjoyed your talk in the collection on influenza.
The subject today is Universal Influenza Vaccines.
As I understand it,
as one of your research projects,
you are committed to attempting to develop a universal influenza vaccine. Is that right?
Prof. Palese: Correct. Absolutely. So, my name is Peter Palese.
I'm Professor and Chair of Microbiology at the Icahn School of Medicine at Mount Sinai,
this is in Manhattan, New York,
and we are working on the development of new and improved influenza virus vaccines.
As you are probably aware of,
influenza virus vaccines have to be administered every year,
and the reason is that the virus,
the influenza viruses, change,
and every year we have to deal with new slightly different variants,
and therefore, we have to administer influenza virus vaccines on an annual basis.
To avoid that and to make vaccines which would last 20 years or a lifetime,
we and others are trying to develop universal influenza virus vaccines.
Interviewer: You're seeking to do this in humans.
Is there any merit in expanding the concept to
animal hosts from which recombinant viruses may emanate?
Prof. Palese: Okay. So this was a very or is a very complex question you are asking.